The European Commission issued marketing authorization approval for Halaven (eribulin) for locally advanced or metastatic breast cancer that has progressed after at least one chemotherapeutic regimen for advanced disease.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
